<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="2" ids="16919">Creatine</z:chebi> mediates remarkable neuroprotection in experimental models of <z:hpo ids='HP_0007354'>amyotrophic lateral sclerosis</z:hpo>, <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's disease</z:e>, <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e>, and traumatic brain injury </plain></SENT>
<SENT sid="1" pm="."><plain>Because caspase-mediated pathways are shared functional mechanistic components in these diseases, as well as in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, we evaluated the effect of <z:chebi fb="2" ids="16919">creatine</z:chebi> supplementation on an experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="2" pm="."><plain>Oral <z:chebi fb="2" ids="16919">creatine</z:chebi> administration resulted in a remarkable reduction in ischemic <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and neuroprotection after <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice </plain></SENT>
<SENT sid="3" pm="."><plain>Postischemic caspase-3 activation and <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release were significantly reduced in <z:chebi fb="2" ids="16919">creatine</z:chebi>-treated mice </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="2" ids="16919">Creatine</z:chebi> administration buffered <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-mediated cerebral ATP <z:mpath ids='MPATH_63'>depletion</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>These data provide the first direct correlation between the preservation of bioenergetic cellular status and the inhibition of activation of caspase cell-<z:hpo ids='HP_0011420'>death</z:hpo> pathways in vivo </plain></SENT>
<SENT sid="6" pm="."><plain>An alternative explanation to our findings is that <z:chebi fb="2" ids="16919">creatine</z:chebi> is neuroprotective through other mechanisms that are independent of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> cell-<z:hpo ids='HP_0011420'>death</z:hpo> pathways, and therefore postischemic ATP preservation is the result of tissue sparing </plain></SENT>
<SENT sid="7" pm="."><plain>Given its safety record, <z:chebi fb="2" ids="16919">creatine</z:chebi> might be considered as a novel therapeutic agent for inhibition of ischemic brain injury in humans </plain></SENT>
<SENT sid="8" pm="."><plain>Prophylactic <z:chebi fb="2" ids="16919">creatine</z:chebi> supplementation, similar to what is recommended for an agent such as aspirin, may be considered for patients in high <z:hpo ids='HP_0001297'>stroke</z:hpo>-risk categories </plain></SENT>
</text></document>